The Role of Bcl-xL Protein Research in Veterinary Oncology

Case report: BCL-2 and CD31 immunoexpression related to clinical and histopathological evaluation of renal dysplasia in a Welsh Corgi Puppy

A case of renal dysplasia (RD) in the Welsh Corgi dog has been reported. Clinically, the affected 3-month-old, female, Welsh Corgi dog showed unclear symptoms of chronic kidney disease. Grossly, both left and right kidneys revealed cystic hypoplasia. Histologically, the primary lesions included immature or fetal glomeruli/tubules, proliferative arterioles, persistent metanephric ducts, persistent mesenchyme, and atypical tubular epithelium were presented. A group of degenerative and inflammatory lesions consisting of interstitial nephritis, interstitial fibrosis, and mineralization of tubules were found. Immunohistochemically, the epithelial cells of immature (fetal) tubules had BCL-2 labeling whereas CD31 (PECAM-1) was labeled in the endothelial cells of the proliferative arterioles. The immunohistochemical findings were confirmed and consolidated with the routine histopathological findings. This study was the first demonstration of the clinical, histopathological, and immunohistochemical features of RD disease in a Welsh Corgi puppy.

DNA Damage Response (DDR) proteins in canine cancer as potential research targets in comparative oncology

The DNA damage response (DDR) is a complex signal transduction network that is activated when endogenous or exogenous genotoxins damage or interfere with the replication of genomic DNA. Under such conditions, the DDR promotes DNA repair and ensures accurate replication and division of the genome. High levels of genomic instability are frequently observed in cancers and can stem from germline loss‐of‐function mutations in certain DDR genes, such as BRCA1, BRCA2, and p53, that form the basis of human cancer predisposition syndromes. In addition, mutation and/or aberrant expression of multiple DDR genes are frequently observed in sporadic human cancers. As a result, the DDR is considered to represent a viable target for cancer therapy in humans and a variety of strategies are under investigation. Cancer is also a significant cause of mortality in dogs, a species that offers certain advantages for experimental oncology. Domestic dogs present numerous inbred lines, many of which display predisposition to specific forms of cancer and the study of which may provide insight into the biological basis of this susceptibility. In addition, clinical trials are possible in dogs and may lead to therapeutic insights that could ultimately be extended to humans. Here we review what is known specifically about the DDR in dogs and discuss how this knowledge could be extended and exploited to advance experimental oncology in this species.